CDEK
← All drugs Report issue

deferoxamine

Trade name: desferal

Small moleculeapproved

Approved

Apr 1, 1968

Deferoxamine (brand name Desferal) an iron chelator, is a drug for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Deferoxamine chelates iron by forming a stable complex that prevents the iron entering into further chemical reactions. However, drug may cause hypersensitivity reactions, systemic allergic reactions, and cardiovascular, hematologic and neurological adverse reactions. Serious adverse reactions include significant hypotension and marked body weight loss. Principally plasma enzymes metabolize deferoxamine, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile. — NCATS

Clinical trial activity

49 trials · 88 clinical orgs · 8 marketing orgs

Phase 1
12
Phase 2
27
Phase 3
8
Phase 4
7

Earliest trial started Jan 1, 1978 (NCT00000595)

Timeline

1960s

  1. Apr 1, 1968

    Novartis — Earliest FDA Approval

  2. Apr 1, 1968

    Novartis — NDA Secondary Org

  3. Apr 1, 1968

    Novartis — NDA Organization

1970s

  1. Jan 1, 1978

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  3. Mar 17, 2004

    Hospira — Marketing Organization

  4. Mar 31, 2006

    Watson Pharmaceuticals — Marketing Organization

  5. Mar 31, 2006

    Dr. Reddy's Laboratories — Marketing Organization

  6. May 30, 2007

    West-Ward Pharmaceutical — Marketing Organization

  7. May 30, 2007

    Hikma — Marketing Organization

  8. Sep 15, 2009

    Fresenius — Marketing Organization

2010s

  1. Sep 29, 2017

    Gland Pharma Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

  • IronCHELATING AGENT

    Iron chelating agent

Approval history

  • approvedPriority reviewApr 1, 1968

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Mol. weight
560.69 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • ba-33112
  • ba-33112
  • deferoxamin
  • deferoxamin
  • deferoxamin
  • deferoxamina
  • deferoxamina
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • deferoxamine
  • déferoxamine
  • déferoxamine
  • deferoxamine hydrochloride
  • deferoxamine mesilate
  • deferoxamine mesilate
  • deferoxamine mesilate
  • deferoxamine mesylate
  • deferoxamine mesylate
  • deferoxamine mesylate
  • deferoxamine mesylate
  • deferoxamine mesylate
  • deferoxaminum
  • deferoxaminum
  • deferrioxamine
  • deferrioxamine
  • deferrioxamine b
  • deferrioxamine b
  • desferal
  • desferal
  • desferal
  • desferal
  • desferal mesylate
  • desferal mesylate
  • desferrioxamine
  • desferrioxamine
  • desferrioxamine
  • desferrioxamine
  • desferrioxamine mesilate
  • desferrioxamine mesilate
  • desferrioxamine mesilate
  • desferrioxamine mesylate
  • desferrioxamine mesylate
  • desferrioxamine mesylate
  • dfo
  • dfo
  • dfoa
  • dfoa
  • dfom
  • dfom

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07162363Phase 2/Phase 3 (Phase 3)Mar 1, 2026University of Illinois at Chicago
NCT07023666Phase 2Oct 7, 2025Inova Health System
NCT06527937Phase 2Jul 17, 2024Aquestive Therapeutics, Frontage Laboratories, Inc.
NCT06468423N/AJan 1, 2023RESnTEC, Institute of Research
NCT05300958Phase 2Mar 21, 2022Sun Yat-Sen University
NCT05184816Phase 1Dec 22, 2021Memorial Sloan-Kettering Cancer Center
NCT04566991Phase 2Feb 28, 2021University of Michigan
NCT04633889Phase 2Feb 28, 2021Harvard University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04389801Phase 4Jun 1, 2020Cairo University
NCT04361032Phase 3May 4, 2020Abderrahmane Mami Hospital, Datametrix, Eshmoun Clinical Research Centre
NCT04333550Phase 1/Phase 2 (Phase 2)Apr 30, 2020Kermanshah University of Medical Sciences
NCT04292314Phase 2/Phase 3 (Phase 3)Nov 1, 2019Beni Suef University, Maternity and Children Hospital, Makkah, University of Arizona
NCT04058197Phase 1/Phase 2 (Phase 2)Aug 31, 2019TauTona Group
NCT03652467Phase 1Sep 1, 2018People's Liberation Army of China
NCT03137966Phase 2Jun 1, 2017Karolinska Institute
NCT02875262Phase 1/Phase 2 (Phase 2)May 1, 2017Radboud University, University of Groningen
NCT03085771Phase 2Jan 1, 2017Karolinska Institute
NCT02367248Phase 1/Phase 2 (Phase 2)Mar 1, 2015Beijing Fangshan District Liangxiang Hospital, Capital Medical University, China Academy of Chinese Medical Sciences, China Medical University, Peking University, People's Liberation Army of China
NCT01996683N/ANov 1, 2014Ain Shams University
NCT02175225Phase 2Oct 1, 2014Case Western Reserve University, Columbia University, Cornell University, Duke University, Harvard University, Henry Ford Health System, Hopital de l'Enfant-Jesus, Icahn School of Medicine at Mount Sinai, Johns Hopkins University, Loyola University, Medical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), New York University, Ohio State University, Oregon Health and Science University, Rhode Island Hospital, Rush University, Stanford University, University of Alberta, University of Arizona, University of Calgary, University of California, San Francisco, University of Connecticut, University of Florida, University of Iowa, University of Massachusetts, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Texas at Houston, University of Washington, Yale University
Showing 20 of 49 trials
Page 1 / 3

Organizations

Research & Development (88)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Harvard UniversityAcademic/Hospital9842005
NovartisFor profit6532003
University of California, San FranciscoAcademic/Hospital4122005
Ain Shams UniversityAcademic/Hospital3322012
Cornell UniversityAcademic/Hospital3112005
Medical University of South CarolinaAcademic/Hospital3022008
National Institute of Neurological Disorders and Stroke (NINDS)Government3022008
University of ArizonaAcademic/Hospital3022013
University of ConnecticutAcademic/Hospital3022008
University of PennsylvaniaAcademic/Hospital3022013
ApotexFor profit2212002
Cairo UniversityAcademic/Hospital2122002
Duke UniversityAcademic/Hospital2012013
Henry Ford Health SystemAcademic/Hospital2012013
Hopital de l'Enfant-JesusAcademic/Hospital2012013
Johns Hopkins UniversityAcademic/Hospital2012013
Karolinska InstituteAcademic/Hospital2212017
LipomedFor profit2222002
National Heart, Lung, and Blood Institute (NHLBI)Government2111978
Ohio State UniversityAcademic/Hospital2012013
88 organizations
Page 1 / 5

Marketing (10)

OrganizationOrg typeRelationshipDate
Dr. Reddy's LaboratoriesFor profitMKTGMar 31, 2006
FreseniusFor profitMKTGSep 15, 2009
Gland Pharma LtdFor profitMKTGSep 29, 2017
Gland Pharma LtdFor profitSYNSep 29, 2017
HikmaFor profitMKTGMay 30, 2007
HospiraFor profitMKTGMar 17, 2004
NovartisFor profitNDA2Apr 1, 1968
NovartisFor profitNDAApr 1, 1968
Watson PharmaceuticalsFor profitMKTGMar 31, 2006
West-Ward PharmaceuticalFor profitMKTGMay 30, 2007